ERAS-0015 for Cancer
(AURORAS-1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, ERAS-0015, to determine its safety and tolerability in individuals with advanced or spreading solid tumors, particularly those with specific RAS mutations. The trial examines ERAS-0015 both as a standalone treatment and in combination with other therapies. It suits patients who have exhausted all available treatments without success or cannot access or tolerate standard treatments. Participants must have tumors with specific mutations and be able to swallow pills. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that ERAS-0015 is being tested for safety in patients with advanced or spreading solid tumors. In early studies using ERAS-0015 alone, researchers aim to find the highest safe dose. They monitor patient tolerance and watch for side effects.
In combination therapy, ERAS-0015 is paired with another experimental drug to assess safety and patient tolerance. As these are early trials, the primary focus remains on safety and determining the optimal dose.
Since ERAS-0015 is in an early testing phase, detailed safety information is still being collected. This ongoing review will enhance understanding of patient tolerance based on trial data.12345Why are researchers excited about this trial's treatments?
Researchers are excited about ERAS-0015 because it offers a fresh approach to cancer treatment. Unlike traditional therapies that often target cancer cells broadly, ERAS-0015 works by precisely targeting specific pathways involved in cancer growth. This targeted mechanism could potentially lead to more effective and less toxic treatments. Additionally, ERAS-0015 is taken orally, which is a more convenient alternative to intravenous chemotherapy, making it easier for patients to incorporate into their daily lives.
What evidence suggests that ERAS-0015 could be an effective treatment for cancer?
Research has shown that ERAS-0015, a new cancer treatment, delivers promising results in lab studies. It blocks RAS signaling, a process that aids the growth of some cancer cells. In these studies, ERAS-0015 effectively reduced tumors both alone and in combination with other treatments. Participants in this trial will receive ERAS-0015 either as a monotherapy with escalating doses or alongside another investigational agent. The treatment is well absorbed and distributed throughout the body, which is crucial for its effectiveness. These early results suggest that ERAS-0015 could be a strong option for treating certain advanced cancers.16789
Who Is on the Research Team?
Gerri Lee
Principal Investigator
Erasca, Inc.
Are You a Good Fit for This Trial?
This trial is for patients with advanced or metastatic solid tumors that have specific RAS mutations. Participants must not have standard treatment options available, or such treatments are intolerable, ineffective, or refused by the patient. They should be able to perform daily activities (ECOG PS of 0 or 1), swallow pills, and have good heart, blood, liver, and kidney function.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Optimization
Dose optimization of ERAS-0015 monotherapy and in combination with other cancer therapies
Pharmacokinetics and Pharmacodynamics Assessment
Assessment of pharmacokinetics and pharmacodynamics of ERAS-0015
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ERAS-0015
Find a Clinic Near You
Who Is Running the Clinical Trial?
Erasca, Inc.
Lead Sponsor